Traders should view this as an expected clinical execution update with no material stock-moving data. The next meaningful catalyst is the preliminary data readout in 2H 2026. Until then, there is no new fundamental information to alter the risk/reward profile.
Price Chart
Executive Summary
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for severe acute lung injury/ARDS. This is a clinical milestone with no revenue or earnings data, and preliminary efficacy readout is not expected until 2H 2026, making the near-term stock impact limited.
Key Facts
- First patient dosed in randomized Phase 2 trial (C-1300-02) for agenT-797 in severe acute lung injury/ARDS patients
- Trial compares agenT-797 + standard of care vs placebo + standard of care; primary endpoints include survival, ventilator-free days, and ICU recovery
- Dosing occurred at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway
- Preliminary data expected in second half of 2026 — no near-term catalyst
- agenT-797 is an off-the-shelf allogeneic iNKT cell therapy, delivered without patient-specific manufacturing or HLA matching
- No financial figures, guidance, or material agreements disclosed in the press release
Financial Impact
No revenue, earnings, or financial guidance disclosed — pre-revenue clinical-stage company with $51M market cap
Risk Factors
- Phase 2 trial may fail to meet endpoints, potentially wiping out clinical value of agenT-797 in this indication
- Enrollment in Ukraine faces geopolitical and operational risks
- Pre-revenue company with limited cash runway — future financing risk exists
- Historical model performance on INKT shows negative average T+20 alpha (-9.76% vs SPY), suggesting the stock has underperformed following prior reports
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access